$SNDX
Syndax Pharmaceuticals Inc

2017 Q1 Form 10-K Financial Statement

#000119312517081863 Filed on March 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2015 Q4 2015 Q3
Revenue $305.0K $305.0K $305.0K
YoY Change 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.930M $2.400M $3.200M
YoY Change -7.96% -46.93%
% of Gross Profit
Research & Development $9.552M $2.587M $2.968M
YoY Change 99.58% 73.57%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $0.00
YoY Change -80.0%
% of Gross Profit
Operating Expenses $13.48M $4.984M $6.163M
YoY Change 48.84% -20.37%
Operating Profit -$13.18M -$4.679M -$5.858M
YoY Change 50.54%
Interest Expense $259.0K -$520.0K -$229.0K
YoY Change 79.86% 663.33%
% of Operating Profit
Other Income/Expense, Net $206.0K -$584.0K -$1.873M
YoY Change -113.06% 18630.0%
Pretax Income -$12.97M -$5.260M -$7.730M
YoY Change 25.56% -0.51%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.97M -$5.263M -$7.731M
YoY Change 25.57% -0.5%
Net Earnings / Revenue -4252.79% -1725.57% -2534.75%
Basic Earnings Per Share
Diluted Earnings Per Share -$711.5K -$302.8K -$445.0K
COMMON SHARES
Basic Shares Outstanding 18.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $95.20M $87.30M $100.5M
YoY Change -29.11% 758.97%
Cash & Equivalents $22.36M $23.18M $54.21M
Short-Term Investments $72.80M $64.10M $46.20M
Other Short-Term Assets $1.600M $800.0K $500.0K
YoY Change 45.45% 66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $97.06M $88.01M $101.3M
YoY Change -28.51% 751.26%
LONG-TERM ASSETS
Property, Plant & Equipment $234.0K $88.00K $100.0K
YoY Change -14.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $376.0K $1.808M $1.500M
YoY Change 73.27% 275.0%
Total Long-Term Assets $610.0K $1.896M $1.500M
YoY Change 23.98% 275.0%
TOTAL ASSETS
Total Short-Term Assets $97.06M $88.01M $101.3M
Total Long-Term Assets $610.0K $1.896M $1.500M
Total Assets $97.67M $89.90M $102.8M
YoY Change -28.32% 735.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.741M $1.452M $1.200M
YoY Change 23.19% 200.0%
Accrued Expenses $7.000M $2.200M $2.700M
YoY Change 94.44% -28.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $8.200M
YoY Change 54.72%
Total Short-Term Liabilities $10.99M $4.847M $13.50M
YoY Change 56.2% 39.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $148.0K $70.00K $18.60M
YoY Change -39.09% 2557.14%
Total Long-Term Liabilities $14.06M $18.36M $18.60M
YoY Change -8.55% 257.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.99M $4.847M $13.50M
Total Long-Term Liabilities $14.06M $18.36M $18.60M
Total Liabilities $25.05M $23.21M $32.10M
YoY Change 11.77% 115.44%
SHAREHOLDERS EQUITY
Retained Earnings -$318.3M -$259.7M
YoY Change 17.38%
Common Stock $390.9M $1.000K
YoY Change 1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.62M -$252.4M $70.80M
YoY Change
Total Liabilities & Shareholders Equity $97.67M $89.90M $102.8M
YoY Change -28.32% 735.77%

Cashflow Statement

Concept 2017 Q1 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$12.97M -$5.263M -$7.731M
YoY Change 25.57% -0.5%
Depreciation, Depletion And Amortization $10.00K $10.00K $0.00
YoY Change -80.0%
Cash From Operating Activities -$12.67M -$4.300M -$5.180M
YoY Change 97.97% 99.23%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K -$10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $11.06M -$17.53M -$7.400M
YoY Change -123.53%
Cash From Investing Activities $11.06M -$17.56M -$7.410M
YoY Change -123.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 120.0K -9.180M 60.06M
YoY Change -99.78% 530.88%
NET CHANGE
Cash From Operating Activities -12.67M -4.300M -5.180M
Cash From Investing Activities 11.06M -17.56M -7.410M
Cash From Financing Activities 120.0K -9.180M 60.06M
Net Change In Cash -1.537M -31.04M 47.47M
YoY Change -15470.0% 585.98%
FREE CASH FLOW
Cash From Operating Activities -$12.67M -$4.300M -$5.180M
Capital Expenditures $0.00 -$30.00K -$10.00K
Free Cash Flow -$12.67M -$4.270M -$5.170M
YoY Change 93.94% 98.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18244423 shares
CY2014Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
4300000
CY2014Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000
CY2016Q2 dei Entity Public Float
EntityPublicFloat
109600000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10104000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-128475000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
680000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10009000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-152569000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
241000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
133000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
698000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
192000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85440 shares
CY2015Q4 us-gaap Assets
Assets
89903000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1769000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
88007000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
48000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47359000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20800000 shares
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
63310000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23179000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
332000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15440000
CY2015Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
63282000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1452000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1220000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
805000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
561000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
28000
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2175000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47359000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14598000
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1452000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
135000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2015Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
258000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
54000
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
18358000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities
Liabilities
23205000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89903000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
70000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4847000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
209000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1808000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9463000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
280000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
63310000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-252415000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.56
CY2015Q4 us-gaap Supplies
Supplies
210000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
280000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18215181 shares
CY2016Q4 us-gaap Assets
Assets
109013000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
0
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2298000
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
319113000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
241000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259675000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1464000
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2848000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
54000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2606195 shares
CY2015Q4 sndx Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
8433000
CY2015Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
574000
CY2015Q4 sndx Reimbursable Costs
ReimbursableCosts
2000
CY2015Q4 sndx Deferred Tax Assets Capitalized Startup And Costs Research And Development Costs
DeferredTaxAssetsCapitalizedStartupAndCostsResearchAndDevelopmentCosts
37641000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1641000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
3000000000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
4000000000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5420000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
27500000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
108510000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
67000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
60323000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
81486000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
389374000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
6000000000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23844000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
604000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14220000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
81430000
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4642348 shares
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2375000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1220000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
243000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1630000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
247000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
56000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
36000000
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6771000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1000000000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
60323000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
7000000000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
0
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13744000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1739000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2531000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
202000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
395000
CY2016Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
306000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
588000
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
168000
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14508000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
396000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Liabilities
Liabilities
24874000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109013000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
288000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10366000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
59000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
390000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
569000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
503000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
524000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
540000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.33
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
81486000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
84139000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.97
CY2016Q4 us-gaap Supplies
Supplies
461000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2234249 shares
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-61669000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
241000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-305293000
CY2014 us-gaap Depreciation
Depreciation
15000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19828000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-95000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-453.02
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2257000
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11157000
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1789000
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y11M16D
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-289000
CY2014 us-gaap Interest Paid
InterestPaid
170000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
40000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2257000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3029000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
151000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
504000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
503000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2503957 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.94
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2560737 shares
CY2016Q4 sndx Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
10530000
CY2016Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
4493000
CY2016Q4 sndx Reimbursable Costs
ReimbursableCosts
262000
CY2016Q4 sndx Deferred Tax Assets Capitalized Startup And Costs Research And Development Costs
DeferredTaxAssetsCapitalizedStartupAndCostsResearchAndDevelopmentCosts
47048000
CY2016Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.800 pure
CY2014Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.081 pure
CY2014 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
614000
CY2014 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-46000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1504000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
5286000
CY2014 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1213000
CY2014 us-gaap Operating Expenses
OperatingExpenses
21332000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-19828000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1888000
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1594000
CY2014 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
14000000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-726000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-64000
CY2014 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
3393000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14393000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26357000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-21332000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12410000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24091000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
33000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2155000
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y10M21D
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1414000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
627000
CY2015 us-gaap Depreciation
Depreciation
21000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7036 pure
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0191 pure
CY2014 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
6529000
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.92
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10175000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2014 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
2257000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58181 shares
CY2014 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
439000
CY2014 sndx Write Off Of Deferred Costs Associated With Postponed Ipo
WriteOffOfDeferredCostsAssociatedWithPostponedIPO
4319000
CY2014 sndx Term Loan Proceeds Allocated To Derivative Liability
TermLoanProceedsAllocatedToDerivativeLiability
130000
CY2015 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
376000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-303000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
762000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3882000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13170000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1519.27
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3882000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11591000
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2015 us-gaap Interest Paid
InterestPaid
688000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3606000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
40506000
CY2015 us-gaap Licenses Revenue
LicensesRevenue
627000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1940000
CY2015 us-gaap Operating Expenses
OperatingExpenses
21140000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-24119000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
87323000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1245000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1045000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1205000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-103845000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9549000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
191000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2015 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2000
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
14000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
69715000
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
9000000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68352 shares
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
3882000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-20513000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
77267000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
102008000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16660000
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6600000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2428000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
118000
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41607 shares
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
5211000
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.6992 pure
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0173 pure
CY2015 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
10011000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.74
CY2015 sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
14000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
126000
CY2016 dei Entity Registrant Name
EntityRegistrantName
SYNDAX PHARMACEUTICALS INC
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001395937
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44444000
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4708000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
665000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.22
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4551000
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
328941000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4708000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
1000
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2016 us-gaap Depreciation
Depreciation
89000
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13321000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Cash and cash equivalents, restricted cash, and short-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#x2019;s cash, cash equivalents, and short-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#x2019;s available-for-sale investments primarily consist of U.S. Treasury securities, U.S. government agency securities, corporate debt securities, certificates of deposit and overnight deposits and potentially subject the Company to concentrations of crdit risk.</p> </div>
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
956000
CY2016 us-gaap Interest Paid
InterestPaid
2000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-706000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
140297000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
1220000
CY2016 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
72000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1703000
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y10M6D
CY2016 us-gaap Licenses Revenue
LicensesRevenue
1220000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4842000
CY2016 us-gaap Operating Expenses
OperatingExpenses
44986000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-44472000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18380000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
923000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1629000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47070000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-43766000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
54202000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
158319000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1220000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13000000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> <b>1. Nature of Business</b></p> <p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"> Syndax Pharmaceuticals, Inc. (the Company) is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications. The Company&#x2019;s lead product candidate, entinostat, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from the Company&#x2019;s Phase 2b clinical trial, ENCORE 301. The Company is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, a monoclonal antibody that targets the colony stimulating factor-1 receptor to enhance the body&#x2019;s immune response on tumors that have shown sensitivity to immunotherapy. The Company is evaluating entinostat as a combination therapeutic in Phase 1b/2 clinical trials with Merck&#xA0;&amp; Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for triple negative breast cancer; and with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. for ovarian cancer. We acquired the exclusive rights to SNDX-6352 in July 2016 and are evaluating SNDX-6352 in a single ascending dose Phase 1 clinical trial. The Company plans to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand our pipeline.</p> <p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> In March 2016, the Company completed its initial public offering (&#x201C;IPO&#x201D;) whereby it sold 4,809,475 shares of common stock at the initial public offering price of $12.00 per share, which included 409,475 shares issued pursuant to the underwriters&#x2019; partial exercise of their over-allotment option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were $50.5 million, net of underwriting discounts and commissions of $4.0 million and offering expenses of $3.1 million. Upon the closing of the IPO, all outstanding shares of the Company&#x2019;s outstanding convertible preferred stock converted into 12,872,551 shares of common stock; and the Company&#x2019;s outstanding warrant liability to purchase 357,840 shares of the Company&#x2019;s common stock valued at $4.6 million was reclassified to additional paid-in capital. The shares trade on the Nasdaq Global Select Market under the symbol &#x201C;SNDX.&#x201D;&#xA0;In connection with the closing of the Company&#x2019;s IPO, the Company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, both of which were approved by the Company&#x2019;s board of directors and stockholders on September&#xA0;28, 2015 and February&#xA0;24, 2016, respectively. Pursuant to the amended and restated certificate of incorporation, the Company is now authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock.</p> <p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company&#x2019;s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before either entinostat or SNDX-6352 is approved, if ever, and the Company begins to generate revenue from sales of entinostat and SNDX-6352. Accordingly, management expects to incur substantial losses on the ongoing development of entinostat and SNDX-6352 and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.</p> <p style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"> &#xA0;</p> <p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> The Company&#x2019;s management believes that the cash, cash equivalents and short-term investments balances as of December&#xA0;31, 2016 should enable the Company to maintain its planned operations for at least the next 12&#xA0;months. The Company&#x2019;s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and general and administrative activities.</p> </div>
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35157000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
261000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
97000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
441573 shares
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.</p> </div>
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7140 pure
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0141 pure
CY2016 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"> <b><i>Guarantees and Indemnifications</i></b></p> <p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"> As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 16) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#x2019;s lease. Through December&#xA0;31, 2016, the Company had not experienced any losses related to these indemnification obligations and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</p> </div>
CY2016 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by $13.0 million and $6.6 million in 2016 and 2015, respectively, due to the increase in deferred tax assets, primarily due to increases in capitalized start-up and research and development costs.
CY2016 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
2598000
CY2016 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
16731 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.64
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
321711000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.87
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
52148000
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.66
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50527000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2058000
CY2016 dei Trading Symbol
TradingSymbol
SNDX
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31665000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
4708000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2058000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3800000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
478530 shares
CY2016 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4000
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
42000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
82415 shares
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14619716 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2016 sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
42000
CY2016 sndx Deferred Tax Assets Operating Loss Carryforwards Expiration Period
DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod
2036
CY2016 sndx Reclassification Of Common Stock Warrant Liability To Additional Paid In Capital
ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital
4551000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-206.30
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2711000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-477000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
4434000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4911000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4434000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1723000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58517 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-440.52
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3288000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-672000
CY2015Q2 us-gaap Licenses Revenue
LicensesRevenue
17000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
5559000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6214000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5542000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2271000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59788 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.85
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4272000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1577000
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
9058000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-10330000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8753000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4786000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4541536 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2808000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
276000
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
8939000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-8358000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8634000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6131000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17769514 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-790.85
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3195000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1873000
CY2015Q3 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
6163000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-7731000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5858000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2968000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71639 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3269000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
269000
CY2016Q3 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
15543000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14969000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15238000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12274000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17899481 shares
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-105.57
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2397000
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-584000
CY2015Q4 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
4984000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-5263000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4679000
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2587000
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83157 shares
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2972000
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
326000
CY2016Q4 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
11446000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-10815000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11141000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8474000
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18193027 shares

Files In Submission

Name View Source Status
0001193125-17-081863-index-headers.html Edgar Link pending
0001193125-17-081863-index.html Edgar Link pending
0001193125-17-081863.txt Edgar Link pending
0001193125-17-081863-xbrl.zip Edgar Link pending
d322633d10k.htm Edgar Link pending
d322633dex231.htm Edgar Link pending
d322633dex311.htm Edgar Link pending
d322633dex312.htm Edgar Link pending
d322633dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g322633g08l98.jpg Edgar Link pending
g322633g18q91.jpg Edgar Link pending
g322633g20v18.jpg Edgar Link pending
g322633g25i69.jpg Edgar Link pending
g322633g52u94.jpg Edgar Link pending
g322633g54b66.jpg Edgar Link pending
g322633g58c16.jpg Edgar Link pending
g322633g62t47.jpg Edgar Link pending
g322633g63f33.jpg Edgar Link pending
g322633g72p48.jpg Edgar Link pending
g322633g88f84.jpg Edgar Link pending
g322633g88h05.jpg Edgar Link pending
g322633g90q19.jpg Edgar Link pending
g322633g94p91.jpg Edgar Link pending
g322633g97g41.jpg Edgar Link pending
g322633g98e51.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-20161231.xml Edgar Link completed
sndx-20161231.xsd Edgar Link pending
sndx-20161231_cal.xml Edgar Link unprocessable
sndx-20161231_def.xml Edgar Link unprocessable
sndx-20161231_lab.xml Edgar Link unprocessable
sndx-20161231_pre.xml Edgar Link unprocessable